Purple Biotech Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PPBT research report →
Price Chart
About the company
Purple Biotech Ltd. , a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1).
- CEO
- Gil Efron
- IPO
- 2015
- Employees
- 10
- HQ
- Rehovot, TA, IL
Get TickerSpark's AI analysis on PPBT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $218.17K
- P/E
- -0.01
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.59
- EV/EBITDA
- -0.97
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -151.75%
- ROIC
- -241.86%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-27,458,000
- Net Income
- $-26,386,000-264.4%
- EPS
- $-11080.00-24967.9%
- OCF Growth
- +61.5%
- FCF Growth
- +61.4%
- 52W High
- $24.00
- 52W Low
- $1.16
- 50D MA
- $1.58
- 200D MA
- $4.55
- Beta
- -0.54
- RSI (14)
- 52
- Avg Volume
- 226.29K
No earnings-call transcripts are available for PPBT yet.
- Free Float
- 94.5%
- Shares Outstanding
- 138.08K
- Float Shares
- 130.52K
of shares held by institutions
20 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Two Sigma Advisers, LP | 14.70K | ▲ 14.70K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Rock Simcha | other | 0 |
| Mar 18, 26 | Rock Simcha | other | 2,650,000 |
| Mar 18, 26 | Zilberberg Suzana | other | 0 |
| Mar 18, 26 | Zilberberg Suzana | other | 2,650,000 |
| Mar 18, 26 | Agmon Ido | other | 0 |
| Mar 18, 26 | Agmon Ido | other | 2,650,000 |
| Mar 18, 26 | Efron Gil | other | 0 |
| Mar 18, 26 | Efron Gil | other | 13,500,000 |
| Mar 18, 26 | Schickler Michael | other | 0 |
| Mar 18, 26 | Schickler Michael | other | 7,100,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PPBT coverage
Recent articles, reports, and earnings notes.
No research on PPBT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PPBT report →Purple Biotech (PPBT) Expected to Announce Quarterly Earnings on Wednesday
defenseworld.net · Aug 4
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
globenewswire.com · Jun 11
Purple Biotech Regains Compliance with Nasdaq
globenewswire.com · Mar 17
Purple Biotech Announces CEO Transition
globenewswire.com · Mar 13
Purple Biotech Announces Plan to Implement ADS Ratio Change
globenewswire.com · Feb 25
Short Interest in Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) Expands By 29.9%
defenseworld.net · Feb 18
Purple Biotech (NASDAQ:PPBT) Shares to Reverse Split on Monday, March 2nd
defenseworld.net · Feb 14
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
globenewswire.com · Dec 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.